LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
People with CF aged ≥12 years in the UK who initiated ELX/TEZ/IVA had sustained improvements in multiple CF-related health outcomes, consistent with results from clinical trials. These results support the positive impact of ELX/TEZ/IVA on the lives of people with CF.
Authors
- Connor J. Haugh (ORCID: https://orcid.org/0000-0002-5204-8271)
- Siân Clarke (ORCID: https://orcid.org/0009-0008-2805-930X)
- G. Vega-Hernández
- S.B. Carr (ORCID: https://orcid.org/0000-0003-0580-2478)
- Susan C. Charman (ORCID: https://orcid.org/0000-0002-1887-9311)
- Gordon MacGregor (ORCID: https://orcid.org/0000-0002-8455-3424)
- Heike Wöhling
- Andrew Wilfin
- Carl A. Baxter
- Francis Adams
Institutions
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Cystic Fibrosis Trust (GB)
- Vertex Pharmaceuticals (United Kingdom) (GB)
- Queen Elizabeth University Hospital (GB)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1016/j.jcf.2025.04.012
- Citations
- 7
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 10.63
Funders
- Vertex Pharmaceuticals